![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, January 16, 2023 12:44:11 PM
Regeneron's presentation stated that in the U.S. alone, millions of immuno-compromised people will not adequately respond to vaccination.
And antibodies can be dosed prophylactically to prevent infection and severe COVID-19 disease.
On slide #27, the Company stated its 'Next-gen COVID antibody binds outside variable RBD and has demonstrated high neutralization activity against all known variants and lineages and disclosed it anticipates initiating the REGN14287 phase 3 clinical trial in 2023, pending regulatory discussions.
The NCT04425629 study was last updated on July 29, 2022.
https://www.precisionvaccinations.com/2023/01/11/regenerons-next-gen-monoclonal-antibody-revealed
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM